Aduro BioTech

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aduro Biotech (KDNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aduro Biotech (KDNY) Upgraded to Buy: What Does It Mean for the Stock?

Aduro Biotech (KDNY) delivered earnings and revenue surprises of -291.30% and 37.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (KDNY) Reports Q3 Loss, Tops Revenue Estimates

Aduro Biotech (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aduro Biotech (KDNY) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aduro Biotech (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aduro Biotech (KDNY) Upgraded to Buy: Here's What You Should Know

Does Aduro Biotech (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Aduro Biotech (KDNY)

Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”

Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

One-for-Five Reverse Stock Split to be Effective October 2, 2020

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech.

Chinook Therapeutics raises $106M as it prepares to merge with Aduro Biotech

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates

BERKELEY, Calif., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand (APRIL) and Stimulator of Interferon Genes (STING) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2020.

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

BERKELEY, Calif., June  24, 2020  (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors.

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, has agreed to merge with Berkeley, Calif.

Chinook Therapeutics to merge with Aduro Biotech as it pushes forward with kidney disease therapies

BERKELEY, Calif., June  02, 2020  (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of healthy volunteer data from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy as well as data from long-term nonclinical studies. The findings are being presented as posters at the 57th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Fully Virtual Congress.

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Aduro Biotech's Shares March Higher, Can It Continue?

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?

Is  (ADRO) Outperforming Other Medical Stocks This Year?

Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (ADRO) Reports Q1 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?

Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.

Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know

Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year?

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

News for Aduro BioTech Stock (ADRO)